SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA issues 3 observations for Sun Pharmaceutical’s Halol facility

23 Feb 2018 Evaluate

The United States Food & Drug Administration (USFDA) has issued three observations to Sun Pharmaceutical Industries through form 483 for its Halol facility, Gujarat, India. The USFDA had conducted a Good Manufacturing Practices (GMP) inspection at Halol facility from February 12, 2018 to February 23, 2018.

The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days. The company is committed to addressing these observations promptly.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1834.40 -16.00 (-0.86%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×